Your browser doesn't support javascript.
loading
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano, Luigi; Lu, Yao; Servetto, Alberto; Hanker, Ariella B; Jansen, Valerie M; Bauer, Joshua A; Sudhan, Dhivya R; Guerrero-Zotano, Angel L; Croessmann, Sarah; Guo, Yan; Ericsson, Paula Gonzalez; Lee, Kyung-Min; Nixon, Mellissa J; Schwarz, Luis J; Sanders, Melinda E; Dugger, Teresa C; Cruz, Marcelo Rocha; Behdad, Amir; Cristofanilli, Massimo; Bardia, Aditya; O'Shaughnessy, Joyce; Nagy, Rebecca J; Lanman, Richard B; Solovieff, Nadia; He, Wei; Miller, Michelle; Su, Fei; Shyr, Yu; Mayer, Ingrid A; Balko, Justin M; Arteaga, Carlos L.
Affiliation
  • Formisano L; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Lu Y; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Servetto A; UTSW Simmons Cancer Center, Dallas, TX, 75230, USA.
  • Hanker AB; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Jansen VM; UTSW Simmons Cancer Center, Dallas, TX, 75230, USA.
  • Bauer JA; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Sudhan DR; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Guerrero-Zotano AL; Departments of Biochemistry, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Croessmann S; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Guo Y; UTSW Simmons Cancer Center, Dallas, TX, 75230, USA.
  • Ericsson PG; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Lee KM; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Nixon MJ; Vanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, 37232-6307, TN, USA.
  • Schwarz LJ; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Sanders ME; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Dugger TC; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Cruz MR; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Behdad A; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Cristofanilli M; Departments of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • Bardia A; Departments of Medicine, Vanderbilt University Medical Center, Nashville, 37232-6307, TN, USA.
  • O'Shaughnessy J; Robert H Lurie Comprehensive Cancer Center, Chicago, 60611, IL, USA.
  • Nagy RJ; Robert H Lurie Comprehensive Cancer Center, Chicago, 60611, IL, USA.
  • Lanman RB; Robert H Lurie Comprehensive Cancer Center, Chicago, 60611, IL, USA.
  • Solovieff N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, 02114, MA, USA.
  • He W; Baylor University Medical Center, Texas Oncology, , US Oncology, Dallas, 75246, TX, USA.
  • Miller M; Guardant Health, Redwood City, 94063, CA, USA.
  • Su F; Guardant Health, Redwood City, 94063, CA, USA.
  • Shyr Y; Novartis Institutes for Biomedical Research, Cambridge, 02139, MA, USA.
  • Mayer IA; Novartis Institutes for Biomedical Research, Cambridge, 02139, MA, USA.
  • Balko JM; Novartis Pharmaceuticals Corporation, East Hanover, 07936, NJ, USA.
  • Arteaga CL; Novartis Pharmaceuticals Corporation, East Hanover, 07936, NJ, USA.
Nat Commun ; 10(1): 1373, 2019 03 26.
Article in En | MEDLINE | ID: mdl-30914635
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Drug Resistance, Neoplasm / Receptor, Fibroblast Growth Factor, Type 1 / Receptor, Fibroblast Growth Factor, Type 2 / Circulating Tumor DNA Type of study: Prognostic_studies Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Drug Resistance, Neoplasm / Receptor, Fibroblast Growth Factor, Type 1 / Receptor, Fibroblast Growth Factor, Type 2 / Circulating Tumor DNA Type of study: Prognostic_studies Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom